Research & Development
AI concurs with humans in heart failure test, suggesting scalable approach to clinical trials
Artificial intelligence (AI) may make clinical trials more efficient by accurately identifying events at scale, a retrospective analysis has found.
November 21, 2023
Measuring NT-proBNP changes over time may improve risk stratification for heart patients
Measuring the changes in the heart hormone precursor N-terminal-pro hormone BNP over time may improve risk stratification and health outcomes for heart patients.
February 8, 2023
Daxor announces results of study showing benefits of blood test for measuring blood volume in heart failure
The study showed a consistent lack of correlation between pulmonary artery diastolic pressure and total blood volume, highlighting the need for accurate volume measurement to provide a complete assessment in guiding clinical management decisions.
January 3, 2023
QuidelOrtho nabs Health Canada approval for high-sensitivity troponin I test on small-footprint analyzer
The test, a fluorescence immunoassay, runs on the Quidel Triage MeterPro platform and provides a quantitative determination of troponin I in whole blood or plasma specimens as an aid in the diagnosis of myocardial infarction.
December 20, 2022
Roche points to results of heart failure study leveraging its cardiac hormone biomarker and test
The results were shared this week at an American Heart Association Late-Breaking Scientific Session and published simultaneously in the Lancet.
November 9, 2022
Daxor highlights study on test in heart failure management
Daxor highlighted results of a study from Duke Heart validating the utility of the firm's diagnostic blood test in optimizing the therapeutic management of heart failure patients.
October 3, 2022
Nordic touts PRO-C6 biomarker for heart failure clinical trials
In collaboration with Bristol Myers Squibb and the University of Pennsylvania, researchers combined analyses of six independent cohorts of HFpEF patients from around the globe, which are being evaluated with the PRO-C6 biomarker.
September 13, 2022
Ortho's Vitros BNP assay gets CE Mark
The test is helpful for use in patients eligible to take the new heart failure combination drug sacubitril/valsartan (Entresto, Novartis) and other neprilysin inhibitors. The product may be used on Ortho's Vitros XT 7600 and Vitros ECi/ECiQ immunodiagnostic systems.
July 22, 2019
Panel blood test beats gold standard BNP in heart failure
Combined testing with mass spectrometry-based multiple reaction monitoring (MRM) assays for nine known proteins and 16 novel biomarkers was better than measurement of BNP alone in the study of 400 samples from patients with and without heart failure. The full biomarker panel correctly predicted heart failure in blinded patient samples, with an accuracy of approximately 82%, reported Dr. Claire Tonry from Queen's University Belfast and colleagues.
June 3, 2019
Page 1 of 1